Drug Profile
Lu 02-750
Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Lundbeck A/S
- Class Antiparkinsonians
- Mechanism of Action Dopamine receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Parkinson's-disease(In volunteers) in Denmark
- 30 Oct 2009 Phase-I clinical trials in Parkinson's disease in Denmark (unspecified route)